Cvrx, Inc.
A maker of implantable medical devices, CVRx builds Barostim, a tiny device that sits under the skin and gently pulses the body's own carotid baroreceptors to ease the symptoms of heart failure — the first device of its kind approved by the FDA. Founded in 2001 by two engineers, it took its name from a mashup of "cardiovascular" and "Rx," the shorthand for prescription or therapy.
The Reporting Person purchased the Shares based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to further increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Issuer's Board of Directors, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Shares, selling some or all of his Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing his intention with respect to any and all matters referred to in Item 4. On August 24, 2026, the Reporting Person delivered a letter (the "Letter") to the Board of Directors of the Issuer (the "Board") urging the Board to retain an independent financial advisor and initiate a review of strategic alternatives, with a sale of the Company as the priority outcome. A copy of the Letter is filed as Exhibit 1 to this Schedule 13D and is incorporated herein by reference.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Chernett Jorey | 13DActivist | 5.5% | 1.46M | Aug 24, 2026 |
The Reporting Person purchased the Shares based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to further increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Issuer's Board of Directors, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Shares, selling some or all of his Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing his intention with respect to any and all matters referred to in Item 4. On August 24, 2026, the Reporting Person delivered a letter (the "Letter") to the Board of Directors of the Issuer (the "Board") urging the Board to retain an independent financial advisor and initiate a review of strategic alternatives, with a sale of the Company as the priority outcome. A copy of the Letter is filed as Exhibit 1 to this Schedule 13D and is incorporated herein by reference. | ||||
| JOHNSON & JOHNSON | 13G/APassive | 15.4% | 4.02M | Jan 12, 2026 |
| Johnson & Johnson Innovation - JJDC, Inc. | 13G/APassive | 15.4% | 4.02M | Jan 12, 2026 |
| New Enterprise Associates 10, Limited Partnership | 13D/AActivist | 7.8% | 2.03M | Feb 20, 2025 |
Not applicable. | ||||
| NEA Partners 10, Limited Partnership | 13D/AActivist | 7.8% | 2.03M | Feb 20, 2025 |
Not applicable. | ||||
| Anthony A. Florence, Jr. | 13D/AActivist | 7.8% | 2.03M | Feb 20, 2025 |
Not applicable. | ||||
| Mohamad H. Makhzoumi | 13D/AActivist | 7.8% | 2.03M | Feb 20, 2025 |
Not applicable. | ||||
| Scott D. Sandell | 13D/AActivist | 7.8% | 2.03M | Feb 20, 2025 |
Not applicable. | ||||
| New Enterprise Associates 8A, Limited Partnership | 13D/AActivist | 0% | 0 | Feb 20, 2025 |
Not applicable. | ||||
| New Enterprise Associates VIII, Limited Partnership | 13D/AActivist | 0% | 0 | Feb 20, 2025 |
Not applicable. | ||||